1. Home
  2. MRNS
  3. MRNS News

Latest Marinus Pharmaceuticals Inc. (MRNS) News on January 19, 2025

Marinus Pharmaceuticals (MRNS) Upgraded to Buy: Here's What You Should Know
MRNS

Zacks

9 days ago

Marinus Pharmaceuticals (MRNS) Upgraded to Buy: Here's What You Should Know

MRNS

MT Newswires

16 days ago

Truist Reinstates Price Target on Marinus Pharmaceuticals at $0.55, Keeps Hold Rating

Marinus Pharmaceuticals to be acquired by Immedica for 55c per share
MRNS

TipRanks

19 days ago

Marinus Pharmaceuticals to be acquired by Immedica for 55c per share

Immedica to buy Marinus Pharmaceuticals for $151m
MRNS

Pharmaceutical Technology

19 days ago

Immedica to buy Marinus Pharmaceuticals for $151m

MRNS

MT Newswires

20 days ago

Sector Update: Health Care Stocks Lower Monday Afternoon

Immedica to Acquire Marinus Pharmaceuticals in $151 Million Deal; Shares Surge 43%
MRNS

GuruFocus.com

20 days ago

Immedica to Acquire Marinus Pharmaceuticals in $151 Million Deal; Shares Surge 43%

MRNS

MT Newswires

20 days ago

Sector Update: Health Care

Marinus Pharma Agrees To $151 Million Acquisition By Immedica: Shares Surge Over 40%
MRNS

Benzinga

20 days ago

Marinus Pharma Agrees To $151 Million Acquisition By Immedica: Shares Surge Over 40%

MRNS

MT Newswires

20 days ago

Sector Update: Health Care

MRNS

MT Newswires

20 days ago

Marinus Pharmaceuticals Shares Up Pre-Bell on Deal to Be Acquired by Immedica Pharma for $0.55 a Share

Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.
MRNS

Business Wire

20 days ago

Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.

US$1.86: That's What Analysts Think Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Is Worth After Its Latest Results
MRNS

Simply Wall St.

2 months ago

US$1.86: That's What Analysts Think Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Is Worth After Its Latest Results

Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates
MRNS

Zacks

2 months ago

Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates

MRNS

Associated Press Finance

2 months ago

Marinus Pharmaceuticals: Q3 Earnings Snapshot

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
MRNS

Business Wire

2 months ago

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

Marinus’ clinical trial of ganaxolone fails to meet primary endpoint
MRNS

Clinical Trials Arena

3 months ago

Marinus’ clinical trial of ganaxolone fails to meet primary endpoint

GSK invests $800M in manufacturing; Amgen sets small discount for Eylea biosimilar
MRNS

BioPharma Dive

3 months ago

GSK invests $800M in manufacturing; Amgen sets small discount for Eylea biosimilar

MRNS

MT Newswires

3 months ago

HC Wainwright Downgrades Marinus Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $2 From $11

MRNS

MT Newswires

3 months ago

TD Cowen Downgrades Marinus Pharmaceuticals to Hold From Buy

MRNS

MT Newswires

3 months ago

Sector Update: Health Care Stocks Decline Late Afternoon

MRNS

MT Newswires

3 months ago

Sector Update: Health Care

MRNS

MT Newswires

3 months ago

Marinus Pharmaceuticals Shares Plunge as Phase 3 Trial of Ganaxolone Fails to Meet Goal; Plans to Cut Costs, Explore Alternatives

MRNS

MT Newswires

3 months ago

Top Midday Decliners

MRNS

MT Newswires

3 months ago

JMP Securities Downgrades Marinus Pharmaceuticals to Market Perform from Outperform

Marinus Pharmaceuticals' Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options
MRNS

Benzinga

3 months ago

Marinus Pharmaceuticals' Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options

Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives
MRNS

Business Wire

3 months ago

Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives

Marinus reports Phase III RAISE trial results for ganaxolone in RSE treatment
MRNS

Clinical Trials Arena

3 months ago

Marinus reports Phase III RAISE trial results for ganaxolone in RSE treatment

Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting
MRNS

Business Wire

3 months ago

Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting

MRNS

MT Newswires

3 months ago

Marinus Pharmaceuticals Gets New US Patent for Ztalmy Titration Regimens; Shares Rise After Hours

Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens
MRNS

Business Wire

3 months ago

Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens

Health Care Roundup: Market Talk
MRNS

The Wall Street Journal

3 months ago

Health Care Roundup: Market Talk

Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting
MRNS

Business Wire

3 months ago

Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
MRNS

Business Wire

3 months ago

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Here’s Why PGIM Jennison Health Sciences Fund Reduced its Position in Marinus Pharmaceuticals (MRNS)
MRNS

Insider Monkey

4 months ago

Here’s Why PGIM Jennison Health Sciences Fund Reduced its Position in Marinus Pharmaceuticals (MRNS)

Great week for Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) institutional investors after losing 78% over the previous year
MRNS

Simply Wall St.

4 months ago

Great week for Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) institutional investors after losing 78% over the previous year

MRNS

MT Newswires

4 months ago

Oppenheimer Upgrades Marinus Pharmaceuticals to Outperform From Perform

Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day
MRNS

Business Wire

4 months ago

Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day

Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024
MRNS

Business Wire

4 months ago

Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024

Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference
MRNS

Business Wire

4 months ago

Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference

Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024
MRNS

Business Wire

5 months ago

Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
MRNS

Simply Wall St.

5 months ago

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Company News for Aug 14, 2024
MRNS

Zacks

5 months ago

Company News for Aug 14, 2024

MRNS

MT Newswires

5 months ago

Ladenburg Thalmann Downgrades Marinus Pharmaceuticals to Neutral From Buy

MRNS

Thomson Reuters StreetEvents

5 months ago

Q2 2024 Marinus Pharmaceuticals Inc Earnings Call

Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Misses Revenue Estimates
MRNS

Zacks

5 months ago

Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Misses Revenue Estimates

MRNS

Associated Press Finance

5 months ago

Marinus Pharmaceuticals: Q2 Earnings Snapshot

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results
MRNS

Business Wire

5 months ago

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

Profound Medical (PROF) Reports Q2 Loss, Misses Revenue Estimates
MRNS

Zacks

5 months ago

Profound Medical (PROF) Reports Q2 Loss, Misses Revenue Estimates

The past three years for Marinus Pharmaceuticals (NASDAQ:MRNS) investors has not been profitable
MRNS

Simply Wall St.

6 months ago

The past three years for Marinus Pharmaceuticals (NASDAQ:MRNS) investors has not been profitable

Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2024 Financial Results on August 13, 2024
MRNS

Business Wire

6 months ago

Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2024 Financial Results on August 13, 2024

Marinus Pharmaceuticals, Inc. (MRNS): A Good One-Dollar Stock According to Street Analysts?
MRNS

Insider Monkey

6 months ago

Marinus Pharmaceuticals, Inc. (MRNS): A Good One-Dollar Stock According to Street Analysts?

MRNS

MT Newswires

6 months ago

Marinus Pharmaceuticals' Ganaxolone Approved in China for Epileptic Seizures

Marinus Pharmaceuticals Announces Ganaxolone Approved in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder
MRNS

Business Wire

6 months ago

Marinus Pharmaceuticals Announces Ganaxolone Approved in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder

PTC Therapeutics (PTCT) Soars 9.7%: Is Further Upside Left in the Stock?
MRNS

Zacks

7 months ago

PTC Therapeutics (PTCT) Soars 9.7%: Is Further Upside Left in the Stock?

Marinus Pharmaceuticals reports data from refractory status epilepticus drug trial
MRNS

Clinical Trials Arena

7 months ago

Marinus Pharmaceuticals reports data from refractory status epilepticus drug trial

MRNS

MT Newswires

7 months ago

Marinus Pharmaceuticals Epilepsy Treatment Falls Short in Phase 3 Study

MRNS

MT Newswires

7 months ago

Top Premarket Decliners

Marinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus
MRNS

Business Wire

7 months ago

Marinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus

Avidity (RNA) Up 33% on Rare Muscle Disease Study Results
MRNS

Zacks

7 months ago

Avidity (RNA) Up 33% on Rare Muscle Disease Study Results

Amgen's (AMGN) Uplizna Meets Study Goal for Rare Disease
MRNS

Zacks

7 months ago

Amgen's (AMGN) Uplizna Meets Study Goal for Rare Disease

J&J's (JNJ) Oral Pill Improves Depression & Insomnia Symptoms
MRNS

Zacks

8 months ago

J&J's (JNJ) Oral Pill Improves Depression & Insomnia Symptoms

Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data
MRNS

Zacks

8 months ago

Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data

Iovance (IOVA) Up 5% on Updated Data From Melanoma Study
MRNS

Zacks

8 months ago

Iovance (IOVA) Up 5% on Updated Data From Melanoma Study

Pfizer (PFE) Starts Another Cost-Cut Plan to Save $1.5B by 2027
MRNS

Zacks

8 months ago

Pfizer (PFE) Starts Another Cost-Cut Plan to Save $1.5B by 2027

MRNS

MT Newswires

8 months ago

Marinus Completes Enrollment in Tuberous Sclerosis Complex Trial; Gets New Patent

Here's Why Marinus Pharmaceuticals (MRNS) is Poised for a Turnaround After Losing -7.8% in 4 Weeks
MRNS

Zacks

8 months ago

Here's Why Marinus Pharmaceuticals (MRNS) is Poised for a Turnaround After Losing -7.8% in 4 Weeks

Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program
MRNS

Business Wire

8 months ago

Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program

After Plunging -7.64% in 4 Weeks, Here's Why the Trend Might Reverse for Marinus Pharmaceuticals (MRNS)
MRNS

Zacks

8 months ago

After Plunging -7.64% in 4 Weeks, Here's Why the Trend Might Reverse for Marinus Pharmaceuticals (MRNS)

Earnings Release: Here's Why Analysts Cut Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Price Target To US$8.00
MRNS

Simply Wall St.

8 months ago

Earnings Release: Here's Why Analysts Cut Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Price Target To US$8.00

Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Lags Revenue Estimates
MRNS

Zacks

8 months ago

Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Lags Revenue Estimates

MRNS

Associated Press Finance

8 months ago

Marinus Pharmaceuticals: Q1 Earnings Snapshot

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
MRNS

Business Wire

8 months ago

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results

MRNS

MT Newswires

8 months ago

HC Wainwright Adjusts Price Target on Marinus Pharmaceuticals to $11 From $27, Maintains Buy Rating

Will Adherex Technologies Inc. (FENC) Report Negative Q1 Earnings? What You Should Know
MRNS

Zacks

9 months ago

Will Adherex Technologies Inc. (FENC) Report Negative Q1 Earnings? What You Should Know

Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference
MRNS

Business Wire

9 months ago

Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference

Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024
MRNS

Business Wire

9 months ago

Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024

Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study
MRNS

Zacks

9 months ago

Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study

Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
MRNS

Business Wire

9 months ago

Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
MRNS

Business Wire

9 months ago

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
MRNS

Business Wire

10 months ago

Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review

Do Options Traders Know Something About Marinus (MRNS) Stock We Don't?
MRNS

Zacks

10 months ago

Do Options Traders Know Something About Marinus (MRNS) Stock We Don't?

Marinus Pharmaceuticals Inc (MRNS) Reports Full Year and Q4 2023 Financial Results
MRNS

GuruFocus.com

10 months ago

Marinus Pharmaceuticals Inc (MRNS) Reports Full Year and Q4 2023 Financial Results

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q4 2023 Earnings Call Transcript
MRNS

Insider Monkey

10 months ago

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q4 2023 Earnings Call Transcript

MRNS

Thomson Reuters StreetEvents

10 months ago

Q4 2023 Marinus Pharmaceuticals Inc Earnings Call

Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Lags Revenue Estimates
MRNS

Zacks

10 months ago

Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Lags Revenue Estimates

MRNS

Associated Press Finance

10 months ago

Marinus Pharmaceuticals: Q4 Earnings Snapshot

Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
MRNS

Business Wire

10 months ago

Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
MRNS

Business Wire

a year ago

Marinus Pharmaceuticals to Present at Upcoming Investor Conferences

Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
MRNS

Business Wire

a year ago

Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
MRNS

Business Wire

a year ago

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Strength Seen in Catalent (CTLT): Can Its 9.7% Jump Turn into More Strength?
MRNS

Zacks

a year ago

Strength Seen in Catalent (CTLT): Can Its 9.7% Jump Turn into More Strength?

Oak Ridge Financial Services, Inc. Announces Fourth Quarter and Full Year 2023 Results and Quarterly Cash Dividend of $0.10 per share
MRNS

GlobeNewswire

a year ago

Oak Ridge Financial Services, Inc. Announces Fourth Quarter and Full Year 2023 Results and Quarterly Cash Dividend of $0.10 per share

Marinus Pharmaceuticals Stock (NASDAQ:MRNS): This Drugmaker Boasts a Rare Treatment
MRNS

TipRanks

a year ago

Marinus Pharmaceuticals Stock (NASDAQ:MRNS): This Drugmaker Boasts a Rare Treatment

Gas prices in 'glacial grind higher' for now — here's why
MRNS

Yahoo Finance

a year ago

Gas prices in 'glacial grind higher' for now — here's why

Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
MRNS

GlobeNewswire

a year ago

Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations

Should You Add Marinus (MRNS) Stock to Your Portfolio Now?
MRNS

Zacks

a year ago

Should You Add Marinus (MRNS) Stock to Your Portfolio Now?

Here's Why Century (CENX) Is a Great 'Buy the Bottom' Stock Now
MRNS

Zacks

a year ago

Here's Why Century (CENX) Is a Great 'Buy the Bottom' Stock Now

CareDx (NASDAQ:CDNA shareholders incur further losses as stock declines 16% this week, taking three-year losses to 89%
MRNS

Simply Wall St.

a year ago

CareDx (NASDAQ:CDNA shareholders incur further losses as stock declines 16% this week, taking three-year losses to 89%

3 Shipping Stocks to Watch From a Challenging Industry
MRNS

Zacks

a year ago

3 Shipping Stocks to Watch From a Challenging Industry

Wall Street Analysts Think Marinus Pharmaceuticals (MRNS) Could Surge 113.01%: Read This Before Placing a Bet
MRNS

Zacks

a year ago

Wall Street Analysts Think Marinus Pharmaceuticals (MRNS) Could Surge 113.01%: Read This Before Placing a Bet

Share on Social Networks: